Evidence map›Paper›PMID 29891600›Full record

ArticleAntimicrobial agents and chemotherapy2018

Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses.

Jeong-Joong Yoon, Mart Toots, Sujin Lee, Myung-Eun Lee, Barbara Ludeke, Jasmina M Luczo, Ketaki Ganti, Robert M Cox, Zachary M Sticher, Vindya Edpuganti and 11 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
142citing papers in PubMed, 3 pooled it
12.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

142 citing papers in PubMed, 3 syntheses or guidelines pooled it, 237 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

82 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 1 country.

Jeong-Joong Yoon *Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.
Mart Toots *Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.
Sujin LeeDepartment of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
Myung-Eun LeeInstitute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.
Barbara LudekeDepartment of Microbiology, Boston University School of Medicine, Boston, Massachusetts, USA.
Jasmina M LuczoCenter for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA.
Ketaki GantiDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.
Robert M CoxInstitute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.
Zachary M SticherEmory Institute for Drug Development, Emory University, Atlanta, Georgia, USA.
Vindya EdpugantiEmory Institute for Drug Development, Emory University, Atlanta, Georgia, USA.
Deborah G MitchellEmory Institute for Drug Development, Emory University, Atlanta, Georgia, USA.
Mark A LockwoodEmory Institute for Drug Development, Emory University, Atlanta, Georgia, USA.
Alexander A KolykhalovEmory Institute for Drug Development, Emory University, Atlanta, Georgia, USA.
Alexander L GreningerVirology Division, Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA.
Martin L MooreDepartment of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
George R PainterEmory Institute for Drug Development, Emory University, Atlanta, Georgia, USA.
Anice C LowenDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0002-9829-112X
Stephen M TompkinsCenter for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA.ORCID 0000-0002-1523-5588
Rachel FearnsDepartment of Microbiology, Boston University School of Medicine, Boston, Massachusetts, USA.
Michael G NatchusEmory Institute for Drug Development, Emory University, Atlanta, Georgia, USA.
Richard K PlemperInstitute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA rplemper@gsu.edu.
Emory University · USGeorgia State University · USBoston University · USUniversity of Georgia · USUniversity of Washington · US

Funding

BIOLOGY OF THE LUNG--MULTIDISCIPLINARY PROGRAMT32HL007035 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Darrell N. Kotton, JOSEPH P MIZGERD · 1985 to 2026
$24.3M
Identification and Pre-Clinical Evaluation of Measles Virus InhibitorsR01AI071002 · NIAID · GEORGIA STATE UNIVERSITY · PI PLEMPER, RICHARD K. · 2006 to 2022
$6.6M
Development of a Broad-Spectrum Inhibitor against Seasonal and Highly-Pathogenic Influenza VirusesR01AI141222 · NIAID · GEORGIA STATE UNIVERSITY · PI PLEMPER, RICHARD K. · 2019 to 2023
$5.0M
Novel Therapeutics against Respiratory Syncytial Virus InfectionR01HD079327 · NICHD · GEORGIA STATE UNIVERSITY · PI PLEMPER, RICHARD K. · 2014 to 2018
$2.8M
Identification and Hit-to-Lead Development of Influenza A Virus InhibitorsR21AI119196 · NIAID · GEORGIA STATE UNIVERSITY · PI PLEMPER, RICHARD K. · 2015 to 2016
$436k
NHLBI NIH HHS T32 HL007035NIAID NIH HHS HHSN272201500008CNIAID NIH HHS R01 AI071002NIAID NIH HHS R01 AI141222NIAID NIH HHS R21 AI119196NICHD NIH HHS R01 HD079327
6 · The paper itself

Abstract

Morbidity and mortality resulting from influenza-like disease are a threat, especially for older adults. To improve case management, next-generation broad-spectrum antiviral therapeutics that are efficacious against major drivers of influenza-like disease, including influenza viruses and respiratory syncytial virus (RSV), are urgently needed. Using a dual-pathogen high-throughput screening protocol for influenza A virus (IAV) and RSV inhibitors, we have identified

Indexed as

AnimalsAntiviral AgentsCells, CulturedGuinea PigsHumansInfluenza A virusInfluenza B virusMiceRespiratory Syncytial VirusesRespiratory Syncytial Virus, HumanRNA, ViralAntiviral AgentsRNA, Viralantiviral agentsinfluenzanucleoside analogsrespiratory syncytial virus

Identifiers

PMID29891600
PMCPMC6105843
OpenAlexW2807193652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.